2 Classen Patents Pass Bilski Test: Fed. Circ.
After a remand by the U.S. Supreme Court in light of last year's Bilski decision, the Federal Circuit on Wednesday upheld two of Classen Immunotherapies Inc.'s patents for evaluating a vaccine...To view the full article, register now.
Already a subscriber? Click here to view full article